DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Early evidence suggests GLP-1s reduce opioid craving. Mechanism may involve dopamine pathway modulation. Phase 2 trials underway.
Small open-label studies show 30-40% craving reduction in OUD patients on GLP-1s. NIH-funded Phase 2 trial enrolling 2025. No Phase 3 yet.
Addiction medicine, NIH. Used off-label by some practitioners for refractory OUD alongside MAT (buprenorphine/methadone).
Not a replacement for MAT. Naloxone access, behavioral therapy, and overdose prevention remain primary. Mechanism speculative.
Watch this space. Mechanistic plausibility is high, evidence is early. Not yet a viable off-label option.
Editorial summary. Off-label use is legal but not FDA-evaluated. Insurance typically does not cover off-label prescriptions. Not medical advice.